Chiusura precedente | 945,50 |
Aperto | 937,50 |
Denaro | 942,30 x 0 |
Lettera | 956,70 x 0 |
Min-Max giorno | 933,70 - 947,90 |
Intervallo di 52 settimane | 620,80 - 976,10 |
Volume | |
Media Volume | 410.285 |
Capitalizzazione | 2,113T |
Beta (5 anni mensile) | 0,35 |
Rapporto PE (ttm) | 40,46 |
EPS (ttm) | 23,18 |
Prossima data utili | N/D |
Rendimento e dividendo (forward) | 11,15 (1,19%) |
Data ex dividendo | 12 ago 2022 |
Stima target 1A | N/D |
Bagsværd, Denmark, 23 January 2023 – On 4 November 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 24 billion to be executed during a 12-month period beginning 2 February 2022. Under the programme
NEW YORK, Jan. 12, 2023 (GLOBE NEWSWIRE) -- ExlService Holdings, Inc. (NASDAQ: EXLS), a leading global data analytics and digital operations and solutions company, today announced that Andreas Fibig, a seasoned global executive with a strong record of innovation across industries and geographies, has been appointed to EXL’s Board of Directors as an independent director effective Jan. 10, 2023. Fibig will be a member of the Board’s Audit and Nominating and Governance Committees. “Andreas is a dis
Novo Nordisk A/S – Share repurchase programme Bagsværd, Denmark, 22 December 2022 – On 4 November 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 24 billion to be executed during a 12-month period